The initial success of the copyright undeniably revolutionized the drug landscape, but placing funds in companies heavily reliant on generic versions presents a uncertain picture. While early earnings were impressive, the end of patents and the rise of discounted alternatives have diminished market share. Thus, a thorough assessment of present inco